Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28344
Title: Higher Coffee Consumption Is Associated With Slower Cognitive Decline and Less Cerebral Aβ-Amyloid Accumulation Over 126 Months: Data From the Australian Imaging, Biomarkers, and Lifestyle Study.
Austin Authors: Gardener, Samantha L;Rainey-Smith, Stephanie R;Villemagne, Victor L ;Fripp, Jurgen;Doré, Vincent ;Bourgeat, Pierrick;Taddei, Kevin;Fowler, Christopher;Masters, Colin L ;Maruff, Paul;Rowe, Christopher C ;Ames, David;Martins, Ralph N
Affiliation: The Florey Institute of Neuroscience and Mental Health
Molecular Imaging and Therapy
CSIRO Health and Biosecurity/Australian e-Health Research Centre, Herston, QLD, Australia
Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, United States
Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute, Perth, WA, Australia
Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, WA, Australia
School of Psychological Science, University of Western Australia, Perth, WA, Australia
Department of Biomedical Sciences, Macquarie University, Sydney, NSW, Australia
Cogstate Ltd., Melbourne, VIC, Australia
National Ageing Research Institute, Parkville, VIC, Australia
Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne, VIC, Australia
Issue Date: 19-Nov-2021
Date: 2021
Publication information: Frontiers in Aging Neuroscience 2021; 13: 744872.
Abstract: Background: Worldwide, coffee is one of the most popular beverages consumed. Several studies have suggested a protective role of coffee, including reduced risk of Alzheimer's disease (AD). However, there is limited longitudinal data from cohorts of older adults reporting associations of coffee intake with cognitive decline, in distinct domains, and investigating the neuropathological mechanisms underpinning any such associations. Methods: The aim of the current study was to investigate the relationship between self-reported habitual coffee intake, and cognitive decline assessed using a comprehensive neuropsychological battery in 227 cognitively normal older adults from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) study, over 126 months. In a subset of individuals, we also investigated the relationship between habitual coffee intake and cerebral Aβ-amyloid accumulation (n = 60) and brain volumes (n = 51) over 126 months. Results: Higher baseline coffee consumption was associated with slower cognitive decline in executive function, attention, and the AIBL Preclinical AD Cognitive Composite (PACC; shown reliably to measure the first signs of cognitive decline in at-risk cognitively normal populations), and lower likelihood of transitioning to mild cognitive impairment or AD status, over 126 months. Higher baseline coffee consumption was also associated with slower Aβ-amyloid accumulation over 126 months, and lower risk of progressing to "moderate," "high," or "very high" Aβ-amyloid burden status over the same time-period. There were no associations between coffee intake and atrophy in total gray matter, white matter, or hippocampal volume. Discussion: Our results further support the hypothesis that coffee intake may be a protective factor against AD, with increased coffee consumption potentially reducing cognitive decline by slowing cerebral Aβ-amyloid accumulation, and thus attenuating the associated neurotoxicity from Aβ-amyloid-mediated oxidative stress and inflammatory processes. Further investigation is required to evaluate whether coffee intake could be incorporated as a modifiable lifestyle factor aimed at delaying AD onset.
URI: https://ahro.austin.org.au/austinjspui/handle/1/28344
DOI: 10.3389/fnagi.2021.744872
ORCID: 0000-0002-8051-0558
0000-0003-1397-0359
0000-0003-3072-7940
0000-0003-3910-2453
0000-0002-6947-9537
Journal: Frontiers in Aging Neuroscience
PubMed URL: 34867277
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/34867277/
ISSN: 1663-4365
Type: Journal Article
Subjects: AIBL
Alzheimer’s disease
Australian Imaging Biomarkers and Lifestyle flagship study of ageing
Aβ-amyloid
caffeine
coffee
cognitive decline
dementia
Appears in Collections:Journal articles

Show full item record

Page view(s)

42
checked on Dec 11, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.